References
- 1LuquinMRScipioniOVaamondeJGershanikOObesoJALevodopa-induced dyskinesias in Parkinson's disease: Clinical and pharmacological classificationMove Disord11992711712410.1002/mds.870070204
- 2MarconiRLefebvre-CaparrosDBonnetAVidailhetMDuboisBAgidYLevodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiologyMove Disord1994921210.1002/mds.870090103
- 3RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEA five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopaN Engl J Med20003421484149110.1056/NEJM20000518342200410816186
- 4StocchiFTagliatiMOlanowCWTreatment of levodopa-induced motor complicationsMove Disord200823(S3)S599S61210.1002/mds.22052
- 5WattsRLLyonsKEPahwaRet alOnset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's diseaseMove Disord20102585886610.1002/mds.22890
- 6da Silva-JuniorFPBraga-NetoPSueli MonteFde BruinVMAmantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled studyParkinsonism Relat Disord20051144945210.1016/j.parkreldis.2005.05.00816154788
- 7SchragAHovrisAMorleyDQuinnNJahanshahiMYoung- versus older-onset Parkinson's disease: Impact of disease and psychosocial consequencesMove Disord2003181250125610.1002/mds.10527
- 8D LMcLellanB CDeanImproved control of brittle Parkinsonism by separate administration of levodopa and benserazideBMJ19822841001100210.1136/bmj.284.6321.10016802383
- 9KosticVPrzedborskiSFlasterESternicNEarly development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's diseaseNeurology199141Pt 120220510.1212/WNL.41.2_Part_1.2021992362
- 10PrashanthLKFoxSMeissnerWGl-Dopa-induced dyskinesia-clinical presentation, genetics, and treatmentInt Rev Neurobiol201198315410.1016/B978-0-12-381328-2.00002-X21907082
- 11TambascoNSimoniSMarsiliEet alClinical aspects and management of levodopa-induced dyskinesiaParkinsons Dis2012201274594722701811
- 12ZhengZLiYLiJet alStimulation-induced dyskinesia in the early stage after subthalamic deep brain stimulationStereotact Funct Neurosurg201088293410.1159/00026007719940547
- 13McClellandS
3rd KimBWinfieldLMet alMicroelectrode recording-determined subthalamic nucleus length not predictive of stimulation-induced side effectsNeurosurg Focus200519E1316398463 - 14GagoMFRosasMJLinharesPet alTransient disabling dyskinesias: A predictor of good outcome in subthalamic nucleus deep brain stimulation in Parkinson's diseaseEur Neurol200961949910.1159/00017794119039227
- 15MerelloMPerez-LloretSAnticoJObesoJADyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadineJ Neurol Neurosurg Psychiatry20067717217410.1136/jnnp.2005.06894016421117
- 16DeuschlGSchade-BrittingerCKrackPet alA randomized trial of deep-brain stimulation for Parkinson's diseaseN Engl J Med200635589690810.1056/NEJMoa06028116943402
- 17FollettKAWeaverFMSternMet alPallidal versus subthalamic deep-brain stimulation for Parkinson's diseaseN Engl J Med20103622077209110.1056/NEJMoa090708320519680
- 18OkunMSGalloBVMandyburGet alSubthalamic deep brain stimulation with a constant-current device in Parkinson's disease: An open-label randomised controlled trialLancet Neurol20121114014910.1016/S1474-4422(11)70308-822239915
- 19WeaverFMFollettKASternMet alRandomized trial of deep brain stimulation for Parkinson disease: Thirty-six-month outcomesNeurology201279556510.1212/WNL.0b013e31825dcdc122722632
- 20KanoTKatayamaYKobayashiKet alDetection of boundaries of subthalamic nucleus by multiple-cell spike density analysis in deep brain stimulation for Parkinson's diseaseActa Neurochir Suppl200699333510.1007/978-3-211-35205-2_617370760
- 21Saint-CyrJAHoqueTPereiraLCet alLocalization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imagingJ Neurosurg2002971152116610.3171/jns.2002.97.5.115212450038
- 22HamaniCLozanoAMSpecial lecture: Brain stimulation: Perspectives for the futureClin Neurosurg20045127127415571153
- 23AlvarezLMaciasRPavonNet alTherapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: Results in 89 patients followed for up to 36 monthsJ Neurol Neurosurg Psychiatry20098097998510.1136/jnnp.2008.15494819204026
- 24BouletSLacombeECarcenacCet alSubthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulataJ Neurosci200626107681077610.1523/JNEUROSCI.3065-06.200617050715
- 25NuttJGClinical pharmacology of levodopa-induced dyskinesiaAnn Neurol200047Suppl 1S160–4; discussion S164–6
- 26NuttJGWoodwardWRCarterJHGancherSTEffect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenonArch Neurol1992491123113010.1001/archneur.1992.005303500370161444877
- 27Martinez-RamirezDGiugniJVedam-MaiVet alThe “brittle response” to Parkinson's disease medications: Characterization and response to deep brain stimulation20149e94856